Galectin Therapeutics (GALT) Given Daily News Sentiment Rating of 0.10

Headlines about Galectin Therapeutics (NASDAQ:GALT) have trended somewhat positive recently, Alpha One reports. The research group, a service of Accern, scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Alpha One ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Galectin Therapeutics earned a daily sentiment score of 0.10 on Alpha One’s scale. Alpha One also assigned press coverage about the company an impact score of 8 out of 100, meaning that recent news coverage is extremely unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the news headlines that may have effected Alpha One’s analysis:

A number of equities analysts recently issued reports on GALT shares. Zacks Investment Research raised shares of Galectin Therapeutics from a “hold” rating to a “buy” rating and set a $1.25 price target for the company in a research note on Tuesday, January 10th. FBR & Co reissued a “market perform” rating and issued a $2.00 price target on shares of Galectin Therapeutics in a research note on Monday, February 6th. Finally, HC Wainwright raised shares of Galectin Therapeutics from a “neutral” rating to a “buy” rating and set a $3.50 price target for the company in a research note on Thursday, March 30th.

Shares of Galectin Therapeutics (NASDAQ:GALT) traded down 4.82% during trading on Thursday, hitting $3.16. 671,859 shares of the company’s stock were exchanged. The firm has a 50-day moving average price of $2.10 and a 200-day moving average price of $1.30. The stock’s market cap is $107.64 million. Galectin Therapeutics has a one year low of $0.49 and a one year high of $3.68.

Galectin Therapeutics (NASDAQ:GALT) last posted its earnings results on Tuesday, March 28th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.04. Equities research analysts expect that Galectin Therapeutics will post ($0.58) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was first posted by sleekmoney and is the property of of sleekmoney. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://sleekmoney.com/galectin-therapeutics-galt-given-daily-news-sentiment-rating-of-0-10/1739574.html.

About Galectin Therapeutics

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

5 Day Chart for NASDAQ:GALT

This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/galectin-therapeutics-galt-given-daily-news-sentiment-rating-of-0-10/1739574.html

Receive News & Ratings for Galectin Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *